BioSpace News Archive

Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-978, a CD19/CD3 T-cell engaging antibody construct with a human serum albumin (HSA) binding domain to increase serum half-life.

Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets.

As healthcare professionals continue to battle COVID, the flu, and other respiratory illnesses, hospitals nationwide are gaining on-demand access to therapeutic beds with the latest technology to help patients heal.

AtriCure, Inc. today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023.

Oxular Limited today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug Application (IND) for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME).

bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) today announced publication of “ Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning ” detailing results of the Company’s clinical trial for its non-invasive diagnostic CyPath ® Lung in Respiratory Research, one of the leading peer-reviewed open access journals in the field of respiratory medicine.

Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, announced that it has closed on $25 million of additional equity funding.

Allogene Therapeutics, Inc. today announced that data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory (r/r) multiple myeloma (MM) has been published in Nature Medicine.

HeartBeam, Inc. announced today the appointment of Robert Eno to the newly created position of President.

List Labs, a live biotherapeutics-focused contract development manufacturing organization, adds 500L equipment to expand its bacterial manufacturing capacity.